News

PRE18FFIR was the first multicenter international study to examine prospectively whether non-invasive assessment of coronary atherosclerotic plaque activity predicts recurrent cardiac events in patients with myocardial infarction.

Barcelona, Spain – August 29, 2022: Asundexian 50 mg administered to post-myocardial infarction patients inhibits factor XIa by more than 90% with no significant increase in bleeding, according to late breaking research presented in a...

The Dan-NICAD 2 trial compared the diagnostic performance of stress MPI by 3T cardiac magnetic resonance (CMR) and 82rubidium positron emission tomography (Rb-PET) in patients with suspected obstructive stenosis on coronary CTA using ICA-FFR...

Barcelona, Spain – August 29, 2022: Selection of non-infarct related artery (IRA) lesions for intervention using fractional flow reserve (FFR) is superior to routine angiography-based selection in patients with acute myocardial...

The Causal AI algorithm was used to estimate the effects of LDL and SBP in discrete time units of exposure (conditional on previous exposure to reflect the biology of how atherosclerosis develops) among 1.8 million individuals.

REVIVED-BCIS2 is the first adequately powered randomized trial to examine the efficacy and safety of PCI in patients with LV systolic dysfunction.

In a first-of-its-kind randomized clinical trial, AI proved more successful in assessing and diagnosing cardiac function when compared to echocardiogram assessments made by sonographers.

In this post hoc exploratory analysis of REDUCE-IT, icosapent ethyl (IPE) treatment significantly reduced the risk of fist and total (first and subsequent) primary composite events (CV death, MI, stroke, coronary revascularization, or...

DUBLIN and BARCELONA, Spain – Aug. 29, 2022 –Medtronic plc announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a...

Mount Sinai researchers led the international ENVISAGE-TAVI trial across 173 centers in 14 countries to compare the safety and efficacy of different therapies in AF/TAVR patients who need oral anticoagulation.